# A Phase 2 Study of Oral MKC-1 in Patients With Ovarian or Endometrial Cancer

> **NCT00607607** · PHASE2 · COMPLETED · sponsor: **CASI pharmaceuticals, Inc.** · enrollment: 44 (actual)

## Conditions studied

- Ovarian Cancer
- Endometrial Cancer

## Interventions

- **DRUG:** MKC-1

## Key facts

- **NCT ID:** NCT00607607
- **Lead sponsor:** CASI pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-01
- **Primary completion:** 2011-06
- **Final completion:** 2012-01
- **Target enrollment:** 44 (ACTUAL)
- **Last updated:** 2012-01-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00607607

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00607607, "A Phase 2 Study of Oral MKC-1 in Patients With Ovarian or Endometrial Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00607607. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*